Koh Okamoto

Dr. Koh Okamoto

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
KOKoh Okamoto
Koh Okamoto
YRYoona Rhee
Yoona Rhee
MSMichael Schoeny
Michael Schoeny
KLKaren Lolans
Karen Lolans
JCJennifer Cheng
Jennifer Cheng
FPFor The Centers For Disease Control And Prevention Epicenters Program
For The Centers For Disease Control And Prevention Epicenters Program
Objective: We assessed the impact of personal protective equipment (PPE) doffing errors on healthcare worker (HCW) contamination with multidrug-resistant organisms (MDROs).Design: Prospective, observational study.Setting: The study was conducted at 4 adult ICUs at 1 tertiary-care teaching hospital.Participants: HCWs who cared for patients on contact precautions for methicillin-resistantStaphylococcus aureus(MRSA), vancomycin-resistant Enterococci, or multidrug-resistant gram-negative bacilli were enrolled. Samples were collected from standardized areas of patient body, garb sites, and high-touch environmental surfaces in patient rooms. HCW hands, gloves, PPE, and equipment were sampled before and after patient interaction. Research personnel observed PPE doffing and coded errors based on CDC guidelines.Results: We enrolled 125 HCWs; most were nurses (66.4%) or physicians (19.2%). During the study, 95 patients were on contact precautions for MRSA. Among 5,093 cultured sites (HCW, patient, environment), 652 (14.7%) yielded the target MDRO. Moreover, 45 HCWs (36%) were contaminated with the target MDRO after patient interactions, including 4 (3.2%) on hands and 38 (30.4%) on PPE. Overall, 49 HCWs (39.2%) made multiple doffing errors and were more likely to have contaminated clothes following a patient interaction (risk ratio [RR], 4.69;P= .04). All 4 HCWs with hand contamination made doffing errors. The risk of hand contamination was higher when gloves were removed before gowns during PPE doffing (RR, 11.76;P= .025).Conclusion: When caring for patients on CP for MDROs, HCWs appear to have differential risk for hand contamination based on their method of doffing PPE. An intervention as simple as reinforcing the preferred order of doffing may reduce HCW contamination with MDROs.

14 September 2016 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
KOKoh Okamoto
Koh Okamoto
LPLaurie A. Proia
Laurie A. Proia
PDPatricia L. Demarais
Patricia L. Demarais
Cryptococcusis a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although cases have been described mainly in patients treated with agents that suppress cell-mediated immunity. Ibrutinib is a new biologic agent used for treatment of CLL, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. It acts by inhibiting Bruton’s tyrosine kinase, a kinase downstream of the B-cell receptor critical for B-cell survival and proliferation. Ibrutinib use has not been associated previously with cryptococcal disease. However, recent evidence suggested that treatments aimed at blocking the function of Bruton’s tyrosine kinase could pose a higher risk for cryptococcal infection in a mice model. Here, we report the first case of disseminated cryptococcal disease in a patient with CLL treated with ibrutinib. When evaluating possible infection in CLL patients receiving ibrutinib, cryptococcal disease, which could be life threatening if overlooked, could be considered.

11 April 2017 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
KOKoh Okamoto
Koh Okamoto
MLMichael Y. Lin
Michael Y. Lin
MHManon Haverkate
Manon Haverkate
KLKaren Lolans
Karen Lolans
NMNicholas M. Moore
Nicholas M. Moore
MHMary K. Hayden
Mary K. Hayden
OBJECTIVE: To identify modifiable risk factors for acquisition ofKlebsiella pneumoniaecarbapenemase-producing Enterobacteriaceae (KPC) colonization among long-term acute-care hospital (LTACH) patients.DESIGN: Multicenter, matched case-control study.SETTING: Four LTACHs in Chicago, Illinois.PARTICIPANTS: Each case patient included in this study had a KPC-negative rectal surveillance culture on admission followed by a KPC-positive surveillance culture later in the hospital stay. Each matched control patient had a KPC-negative rectal surveillance culture on admission and no KPC isolated during the hospital stay.RESULTS: From June 2012 to June 2013, 2,575 patients were admitted to 4 LTACHs; 217 of 2,144 KPC-negative patients (10.1%) acquired KPC. In total, 100 of these patients were selected at random and matched to 100 controls by LTACH facility, admission date, and censored length of stay. Acquisitions occurred a median of 16.5 days after admission. On multivariate analysis, we found that exposure to higher colonization pressure (OR, 1.02; 95% CI, 1.01–1.04;P=.002), exposure to a carbapenem (OR, 2.25; 95% CI, 1.06–4.77;P=.04), and higher Charlson comorbidity index (OR, 1.14; 95% CI, 1.01–1.29;P=.04) were independent risk factors for KPC acquisition; the odds of KPC acquisition increased by 2% for each 1% increase in colonization pressure.CONCLUSIONS: Higher colonization pressure, exposure to carbapenems, and a higher Charlson comorbidity index independently increased the odds of KPC acquisition among LTACH patients. Reducing colonization pressure (through separation of KPC-positive patients from KPC-negative patients using strict cohorts or private rooms) and reducing carbapenem exposure may prevent KPC cross transmission in this high-risk patient population.Infect Control Hosp Epidemiol2017;38:670–677

12 September 2020 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
IOItsuki Osawa
Itsuki Osawa
KOKoh Okamoto
Koh Okamoto
MIMahoko Ikeda
Mahoko Ikeda
AOAmato Otani
Amato Otani
YWYuji Wakimoto
Yuji Wakimoto
KMKyoji Moriya
Kyoji Moriya

15 March 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
RYRyo Yamaguchi
Ryo Yamaguchi
TYTakehito Yamamoto
Takehito Yamamoto
KOKoh Okamoto
Koh Okamoto
SHSohei Harada
Sohei Harada
MEMiho Echizenya
Miho Echizenya
TTTappei Takada
Tappei Takada
Limited evidence is available regarding alternative therapeutic agents to vancomycin in treating glycopeptide-susceptible Enterococcus faecium (GSEF) bacteraemia. This study assessed the effectiveness and safety of teicoplanin compared with vancomycin for treating GSEF bacteraemia. This was a retrospective, non-inferiority cohort study. Patients aged ≥18 years who developed GSEF bacteraemia and received either teicoplanin or vancomycin were included. The primary effectiveness outcome was the clinical success at the end of treatment, with a generalized linear model using the propensity score for selecting the agent as a covariate. We used an absolute difference of 20% in clinical success as the non-inferiority margin. Using multivariable logistic regression, the primary safety outcome was the incidence of acute kidney injury (AKI). In total, 164 patients (74 and 90 in the teicoplanin and vancomycin groups, respectively) were included. Overall, 64.9% (48/74) and 48.9% (44/90) of patients in the teicoplanin and vancomycin groups, respectively, achieved the primary effectiveness outcome. A generalized linear analysis showed an adjusted effectiveness difference of 9.9% (95% CI, −0.9% to 20.0%; P = 0.07), indicating non-inferiority of teicoplanin versus vancomycin. The incidence of AKI was 8.1% (6/74) and 24.4% (22/90) in the teicoplanin and vancomycin groups, respectively, with an adjusted OR of 0.242 (95% CI, 0.068 to 0.864; P = 0.029), indicating significantly lower AKI risk in the teicoplanin than in the vancomycin group. Teicoplanin is a safe and useful alternative therapeutic agent for treating GSEF bacteraemia.

4 January 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MIMahoko Ikeda
Mahoko Ikeda
SOShu Okugawa
Shu Okugawa
KKKosuke Kashiwabara
Kosuke Kashiwabara
TMTakashi Moritoyo
Takashi Moritoyo
YKYoshiaki Kanno
Yoshiaki Kanno
KMKyoji Moriya
Kyoji Moriya
To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients with mild-to-moderate COVID-19 pneumonia. Patients were randomly assigned to receive favipiravir alone (n = 24) or nafamostat with favipiravir (n = 21). The outcomes included changes in the World Health Organization clinical progression scale score, time to improvement in body temperature, and improvement in oxygen saturation (SpO2). There was no significant difference in the changes in the clinical progression scale between nafamostat with favipiravir and favipiravir alone groups (median, -0.444 vs -0.150, respectively; least-squares mean difference, -0.294; P = 0.364). The time to improvement in body temperature was significantly shorter in the combination group (5.0 days; 95% confidence interval, 4.0-7.0) than in the favipiravir group (9.0 days; 95% confidence interval, 7.0-18.0; P =0.009). The changes in SpO2 were greater in the combination group than in the favipiravir group (0.526% vs -1.304%, respectively; least-squares mean difference, 1.831; P = 0.022). No serious adverse events or deaths were reported, but phlebitis occurred in 57.1% of the patients in the combination group. Although our study showed no differences in clinical progression, earlier defervescence, and recovery of SpO2 were observed in the combination group.